HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Manal F. Abdelmalek, JaeDuk Choi, Young-Min Kim, Kyounghee Seo, Marcus Hompesch, Seung Jae Baek
Topics & Concepts
Internal medicineFatty liverEndocrinologyGlucagon-like peptide 1 receptorMedicineGlucagon-like peptide-1AgonistType 2 diabetesReceptorDiabetes mellitusDiseaseLiver Disease Diagnosis and TreatmentDiet and metabolism studiesDiabetes Treatment and Management